Potential impact of COVID-19 on the consumption profile of reserve antibacterials - AWaRe in an intensive care unit of a public hospital
DOI:
https://doi.org/10.30968/rbfhss.2023.142.0896Abstract
Objective: To evaluate the variation in consumption of antibacterials (ATB), listed by the National Health Surveillance Agency, components of the reserve group according to the Access, Watch, Reserve (AWaRe) classification of the World Health Organization (WHO), in an Intensive Care Unit (ICU) of a public hospital. Method: This is a quantitative drug utilization study, with retrospective data collection from November/2018 to October/2022. As recommended by the WHO Study Group on Drug Utilization, the Daily Defined Dose (DDD) per 1000 patient-days was used to evaluate the consumption of daptomycin, parenteral linezolid, polymyxin B and E, tigecycline and ceftazidime-avibactam. The DDD were calculated using the WHO standard DDD formula. The analysis period was divided into three phases: pre-pandemic of the COVID-19, acute phase and post-acute phase of the COVID-19 pandemic. The sum of monthly DDD was compared between the three phases. Results: In the ICU of the study hospital, there was an increased consumption of daptomycin and tigecycline during the acute phase, and of all the six ATB during the post-acute phase in comparison to the pre-pandemic period. During the postacute phase, the consumption of daptomycin, linezolid and polymyxin B was higher than the acute phase. The consumption of polymyxin B, polymyxin E and tigecycline was influenced by market instability. The institutional formulary was changed from the acute phase of the pandemic with incorporation of polymyxin E and ceftazidime-avibactam. Conclusion: This study identified variations in the consumption of ATB in the reserve group, which may have been influenced by the COVID-19 pandemic. These data can promote the basis for improvements in local ASP to preserve the effectiveness of these drugs, which should be used as the last therapeutic alternative.
Downloads
References
Organização Pan-America da Saúde (OPAS). Resistência Antimicrobiana. 2020. Available in: https://www.paho.org/pt/topicos/resistencia-antimicrobiana. Accessed in: 29 abr., 2022.
World Health Organization (WHO). WHO Access, Watch, Reserve (AWaRe) classification of antibiotics for evaluation and monitoring of use, 2021. Available in: https://www.who.int/publications/i/item/2021-aware-classification. Accessed in: 10th Jul 2022.
Agência Nacional de Vigilância Sanitária (ANVISA). Orientações para Preenchimento da Avaliação das Práticas de Segurança do Paciente – Serviços de Saúde com UTI - 2022.
European Centre for Disease Prevention and Control (ECDC). Healthcare-associated infections acquired in intensive care units. 2019. Available in: https://www.ecdc.europa.eu/sites/default/files/documents/healthcare-associated-infections-intensive-care-units-annual-epidemiological-report-2019.pdf Accessed in: 19 May 2023.
Oliveira AC, Paula AO, Iquiapaza RA, et al. Infecções relacionadas à assistência em saúde e gravidade clínica em uma unidade de terapia intensiva. Rev Gaúcha Enferm. 2012;33:89-96. DOI:10.1590/S1983-14472012000300012.
World Health Organization (WHO). Defined Daily Dose (DDD). Available in: https://www.who.int/tools/atc-ddd-toolkit/about-ddd. Accessed in: 09 Sep 2022.
Grau S, Echeverria-Esnal D, Gómez-Zorrilla S, et al. Evolution of antimicrobial consumption during the first wave of COVID-19 pandemic. Antibiotics. 2021; 10:132. DOI: 10.3390/antibiotics10020132.
Rawson TM, Ming D, Ahmad R, et al. Antimicrobial use, drug-resistant infections and COVID-19. Nat Rev Microbiol. 2020;18:409-410. DOI:10.1038/s41579-020-0395-y.
Prasad P, Poles J, Zacharioudakis L, et al. Coinfections and antimicrobial use in patients hospitalized with coronavirus disease 2019 (COVID-19) across a single healthcare system in New York City: A retrospective cohort study. Antimicrob Steward Healthc Epidemiol. 2022;2:E78. DOI:10.1017/ash.2022.51
Organização Pan-America da Saúde (OPAS). A Resistência aos antimicrobianos, acelerada pela pandemia de COVID-19. 2021. Available in: https://iris.paho.org/bitstream/handle/10665.2/55936/OPASCDEAMRCOVID19220006_por.pdf?sequence=1&isAllowed=y#:~:text=De%20fato%2C%20foi%20relatado%20um,para%20v%C3%A1rias%20infec%-C3%A7%C3%B5es%20bacterianas%20diferentes. Accessed in: 15th Oct 2022.
Organização Pan-America da Saúde (OPAS). Histórico da pandemia de COVID-19. Available in: https://www.paho.org/pt/COVID19/historico-da-pandemia-COVID-19. Accessed in: 08 Jun 2022.
Barcellos C, Xavier DR. As diferentes fases, os seus impactos e os desafios da pandemia de COVID-19 no Brasil. RECIIS. 2022;16:221–226. DOI: 10.29397/reciis.v16i2.3349.
Hospital Risoleta Tolentino Neves. Risoleta Institucional. Available in: https://www.hrtn.fundep.ufmg.br/institucional/. Accessed in: 08 Jun 2022.
Tacconelli E, Cataldo MA, Paul M, et al. STROBE-AMS: recommendations to optimise reporting of epidemiological studies on antimicrobial resistance and informing improvement in antimicrobial stewardship. BMJ Open. 2016;6:e010134. DOI:10.1136/bmjopen-2015-010134.
Ministério da Saúde. Relação Nacional de Medicamentos Essenciais. 2022.
Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins. Pharmacotherapy. 2019;39:10–39. DOI: 10.1002/phar.2209.
Agência Nacional de Vigilância Sanitária (ANVISA). Boletim segurança do paciente e qualidade em serviços de saúde nº 24 - avaliação dos indicadores nacionais de infecções relacionadas à assistência à saúde (IRAS) e resistência microbiana (RM). 2020. Available in: https://app.powerbi.com/view?r=eyJrIjoiNGUxYWVjOGUtODBmYy00MzJkLWE1MDEt-NWVlYTNmN2Y0ODdhIiwidCI6ImI2N2FmMjNmLWMzZjMtNGQzNS04MGM3LWI3MDg1ZjVlZGQ4MSJ9. Accessed in: 08 Oct 2022.
Sociedade Brasileira de Farmácia Hospitalar e Serviços de Saúde (SBRAFH). Levantamento nacional sobre o abastecimento de medicamentos e produtos para a saúde durante o enfrentamento da pandemia pela COVID-19. Available in: http://www.sbrafh.org.br/inicial/wp-content/uploads/2020/06/OFICIO-037-Ministro-da-Saude-oficial2.pdf. Accessed in: 08 Oct 2022.
Instituto para Práticas Seguras no Uso de Medicamentos (ISMP). Desabastecimento de medicamentos prioritários à assistência ao paciente crítico. 2021. Available in: https://www.ismp-brasil.org/site/wp-content/uploads/2021/06/28abril2021.pdf. Accessed in: 02nd Nov 2022.
Rio Grande do Sul. Lei nº 15.880 de 29 de julho de 2022. Dispõe sobre o fluxo de empréstimo, permuta e doação de medicamentos e fórmulas nutricionais entre estado, municípios e estabelecimentos de saúde no âmbito do estado do Rio Grande do Sul e dá outras providências. 2022.
Stein GE, Babinchak T. Tigecycline: An update. Diagnostic Microbiology and Infectious Disease. 2013;75:331–336. DOI: 10.1016/j.diagmicrobio.2012.12.004.
Fonseca MA, Bertollo CM, Reis AMM, et al. Building an antimicrobial stewardship program: A narrative of six years under the Donabedian perspective. Front Pharmacol. 2023;21:1074389. DOI: 10.3389/fphar.2023.1074389.
Kwon SH, Ahn HL, Han OY, et al. Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull. 2014;37:340–346. DOI: 10.1248/bpb.b13-00109.
Bartal C, Rolston KVI, Nesher L. Carbapenem-resistant Acinetobacter baumannii: colonization, infection and current treatment options. Infect Dis Ther. 2022;11:683–694. DOI: 10.1007/s40121-022-00597-w.
Agência Nacional de Vigilância Sanitária (ANVISA). Nota técnica GVIMS/GGTES/ANVISA Nº 05/2021: orientações para prevenção e controle da disseminação de microrganismos multirresistentes em serviços de saúde no contexto da pandemia da COVID-19. 2021.
Cristina ML, Sartini M, Spagnolo AM. Serratia marcescens Infections in Neonatal Intensive Care Units (NICUs). Int J Environ Res Public Health. 2019;16:610. DOI: 10.3390/ijerph16040610.
Wang Y, Wang J, Wang R, et al. Resistance to ceftazidime–avibactam and underlying mechanisms. J Glob Antimicrob Resist. 2020;22:18-27. DOI: 10.1016/j.jgar.2019.12.009.
Redondo-Bravo L,Gutiérrez-González E, Juan-Sanz IS, et al. Serratia marcescens outbreak in a neonatology unit of a Spanish tertiary hospital: risk factors and control measures. Am J Infect Control. 2019;47:271-279. DOI: 10.1016/j.ajic.2018.08.026
O’Driscoll T, Crank C. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. Infect Drug Resist. 2015;8:217–223. DOI: 10.2147/IDR.S54125.
Taylor SD, Palme M. The action mechanism of daptomycin. Bioorg Med Chem. 2016;24:6253–6268. DOI: 10.1016/j.bmc.2016.05.052.
Renggli L, Gasser M, Plüss-Suard C, et al. Consumption of anti-meticillin-resistant Staphylococcus aureus antibiotics in swiss hospitals is associated with antibiotic stewardship measures. J Hosp Infect. 2021;117:165–171. DOI: 10.1016/j.jhin.2021.08.019.
Colaneri M, Di Carlo D, Amatu A, et al. Ventilator-associated pneumonia due to MRSA vs. MSSA:What should guide empiric therapy? Antibiotics. 2022;11:851. DOI: 10.3390/antibiotics11070851.
Fukushige M, Syue LS, Morikawa K, et al. Trend in healthcare-associated infections due to vancomycin-resistant Enterococcus at a hospital in the era of COVID-19: more than hand hygiene is needed. J Microbiol Immunol Infect. 2022;55:1211-1218. DOI: 10.1016/j.jmii.2022.08.003.
Polly M, Almeida BL, Lennon RP, et al. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. Am J Infect Control. 2022;50:32–38. DOI: 10.1016/j.ajic.2021.09.018.
Parriott A, Kazerouni NN, Epson E. Comparing Hospital Healthcare-Associated Infection Incidence During Pre-COVID-19 Pandemic and Pandemic Eras. Antimicrob Steward Healthc Epidemiol. 2021;1:45-46. DOI: 10.1017/ash.2021.84.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Serlf-archiving policy
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.
